Revised SPC: Paroven (oxerutins) 250 mg Capsules
electronic Medicines Compendium - eMC
electronic Medicines compendium
29 July 2019
The SPC has been updated to advise safety and efficacy of oxerutins (Paroven) in children and adolescents aged less than 18 years has not yet been established, and therefore lower age limit has been changed from 12 years to 18 years.